Open AccessA phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors
Author(s) -
Andrew D.J. Pearson,
Sara M. Federico,
Isabelle Aerts,
Darren Hargrave,
Steven G. DuBois,
Robert Ian,
Ryan Geschwindt,
Ruixue Wang,
Frank G. Haluska,
Tanya Trippett,
Birgit Geoerger
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.12450
Subject(s) - medicine , solid tumor , oncology , cancer research , cancer
Ridaforolimus is an investigational, potent, selective mTOR inhibitor. This study was conducted to determine the recommended phase 2 dose (RP2D), maximum tolerated dose, safety, pharmacokinetics, and antitumor activity of oral ridaforolimus in children with advanced solid tumors.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom